Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability
Launched by MASSACHUSETTS GENERAL HOSPITAL · Aug 4, 2011
Trial Information
Current as of September 01, 2025
Completed
Keywords
ClinConnect Summary
Extensive evidence exists that neurodegeneration begins many years before HD can be diagnosed clinically. Therefore, it is most desirable to begin a neuroprotective therapy before or during this premanifest period with the aim of delaying onset, as well as slowing functional decline. Cellular energy depletion is present early in HD and can be ameliorated by creatine, which helps regenerate cellular ATP. Preclinical evidence for creatine's potential neuroprotective effects in animal models of HD has been well-documented. Before the clinical efficacy of creatine can be tested in premanifest H...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals who have completed the Pre-CREST Study.
- • Individuals capable of providing independent informed consent and complying with trial procedures.
- Exclusion Criteria:
- • -Clinical evidence of unstable medical or psychiatric illness in the investigator's judgment.
- • Additional eligibility criteria apply.
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charlestown, Massachusetts, United States
Patients applied
Trial Officials
Diana Rosas, MD, MS
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials